AU2012321110B2 - Combination treatment - Google Patents

Combination treatment Download PDF

Info

Publication number
AU2012321110B2
AU2012321110B2 AU2012321110A AU2012321110A AU2012321110B2 AU 2012321110 B2 AU2012321110 B2 AU 2012321110B2 AU 2012321110 A AU2012321110 A AU 2012321110A AU 2012321110 A AU2012321110 A AU 2012321110A AU 2012321110 B2 AU2012321110 B2 AU 2012321110B2
Authority
AU
Australia
Prior art keywords
combination
azd5363
pharmaceutically acceptable
cancer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012321110A
Other languages
English (en)
Other versions
AU2012321110A1 (en
Inventor
Barry Robert Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012321110(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to AU2013205648A priority Critical patent/AU2013205648B2/en
Publication of AU2012321110A1 publication Critical patent/AU2012321110A1/en
Application granted granted Critical
Publication of AU2012321110B2 publication Critical patent/AU2012321110B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012321110A 2011-11-30 2012-11-30 Combination treatment Active AU2012321110B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013205648A AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564975P 2011-11-30 2011-11-30
US61/564,975 2011-11-30
PCT/GB2012/052969 WO2013079964A1 (en) 2011-11-30 2012-11-30 Combination treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013205648A Division AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment

Publications (2)

Publication Number Publication Date
AU2012321110A1 AU2012321110A1 (en) 2013-06-20
AU2012321110B2 true AU2012321110B2 (en) 2014-10-23

Family

ID=47295082

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012321110A Active AU2012321110B2 (en) 2011-11-30 2012-11-30 Combination treatment
AU2013205648A Active AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2013205648A Active AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment

Country Status (26)

Country Link
US (2) US20140329786A1 (OSRAM)
EP (1) EP2785349B2 (OSRAM)
JP (1) JP6309454B2 (OSRAM)
KR (1) KR102035361B1 (OSRAM)
CN (1) CN103945849B (OSRAM)
AU (2) AU2012321110B2 (OSRAM)
CA (1) CA2856646C (OSRAM)
CY (1) CY1122624T1 (OSRAM)
DK (1) DK2785349T4 (OSRAM)
ES (1) ES2762250T5 (OSRAM)
FI (1) FI2785349T4 (OSRAM)
HR (1) HRP20191982T4 (OSRAM)
HU (1) HUE046667T2 (OSRAM)
IL (1) IL232530B (OSRAM)
LT (1) LT2785349T (OSRAM)
MX (1) MX367640B (OSRAM)
MY (1) MY175800A (OSRAM)
PH (1) PH12014500943A1 (OSRAM)
PL (1) PL2785349T5 (OSRAM)
PT (1) PT2785349T (OSRAM)
RS (1) RS59493B2 (OSRAM)
RU (1) RU2640485C2 (OSRAM)
SG (1) SG11201401471PA (OSRAM)
SI (1) SI2785349T2 (OSRAM)
SM (1) SMT201900708T1 (OSRAM)
WO (1) WO2013079964A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN102245615A (zh) 2008-10-02 2011-11-16 萨利克斯药品有限公司 治疗肝性脑病的方法
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR101819199B1 (ko) 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
SG10201600077RA (en) 2011-01-11 2016-02-26 Glaxosmithkline Llc Combination
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015049649A1 (en) * 2013-10-01 2015-04-09 Gbglaxosmithkline Intellectual Property (No.2) Limited Combination
US20160235714A1 (en) * 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018015958A1 (en) 2016-07-21 2018-01-25 Hadasit Medical Research Services And Development Ltd. Ar antagonists or inhibitors for use in treating glioblastoma
AU2017376704B2 (en) * 2016-12-16 2021-08-05 Kangpu Biopharmaceuticals, Ltd. Composition, application thereof and treatment method
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
AU2018335391A1 (en) * 2017-09-22 2020-03-26 AustinPx, LLC Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066962A2 (en) * 2003-01-17 2004-08-12 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090163524A1 (en) * 2007-10-11 2009-06-25 Astrazeneca Ab Novel Protein Kinase B Inhibitors - 060
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (OSRAM) 1963-04-04 1900-01-01
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
DK1023050T3 (da) 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
PL338575A1 (en) 1997-08-05 2000-11-06 Pfizer Prod Inc 4-aminopyrrole(3,2-d)pyrimidines as antagonists of neuropeptide y receptor
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO1999062908A2 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
SK17342002A3 (sk) 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
ATE309240T1 (de) 2000-08-31 2005-11-15 Hoffmann La Roche Chinazolin-derivate als alpha-1 adrenerge antagonisten
MEP35308A (en) 2000-12-01 2011-02-10 Osi Pharm Inc COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
UY27220A1 (es) 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
EP1707566A1 (en) 2002-01-07 2006-10-04 Eisai Co., Ltd. Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
MXPA04010640A (es) 2002-05-17 2005-08-16 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario.
US8765783B2 (en) 2002-06-26 2014-07-01 Ono Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
AU2003302657B8 (en) 2002-12-04 2009-12-03 Eisai R&D Management Co., Ltd. Fused 1,3-dihydroimidazole ring compounds
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
WO2004094426A1 (en) 2003-04-21 2004-11-04 Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
KR101332889B1 (ko) 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
EP3719018B1 (en) 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
JP2009534456A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
US20090124610A1 (en) 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AU2010212590B2 (en) * 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
US20120238533A1 (en) * 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
WO2011136828A1 (en) * 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066962A2 (en) * 2003-01-17 2004-08-12 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090163524A1 (en) * 2007-10-11 2009-06-25 Astrazeneca Ab Novel Protein Kinase B Inhibitors - 060
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GODBOLE, A. M. and NJAR, V.C.O., October 12, 2011, Prostate Cancer, retrieved from the internet URL:http://www.hindawi.com/journals/pc/2011/918 *
SARTOR, O., ET AL, The Oncologist, November 2011, Vol. 16, No. 11, pages 1487-1497. First published in The Oncologist Express on November 2, 2011 *
THOMAS, C., ET AL, Urology, September 2011, Vol. 78, Suppl. 3A, Abstract UP-02.098 *

Also Published As

Publication number Publication date
AU2013205648A1 (en) 2013-06-13
HK1202253A1 (en) 2015-09-25
WO2013079964A1 (en) 2013-06-06
EP2785349B2 (en) 2022-11-09
PL2785349T5 (pl) 2023-01-30
SMT201900708T1 (it) 2020-01-14
RS59493B1 (sr) 2019-12-31
IL232530B (en) 2018-07-31
ES2762250T3 (es) 2020-05-22
HUE046667T2 (hu) 2020-03-30
SI2785349T1 (sl) 2019-12-31
MY175800A (en) 2020-07-09
US20140329786A1 (en) 2014-11-06
AU2013205648B2 (en) 2015-02-05
RU2640485C2 (ru) 2018-01-09
KR20140098799A (ko) 2014-08-08
DK2785349T3 (da) 2020-01-02
RS59493B2 (sr) 2023-02-28
BR112014012261A2 (pt) 2017-06-13
EP2785349A1 (en) 2014-10-08
MX2014006547A (es) 2014-07-09
CN103945849A (zh) 2014-07-23
IL232530A0 (en) 2014-06-30
SG11201401471PA (en) 2014-08-28
CY1122624T1 (el) 2021-03-12
EP2785349B1 (en) 2019-10-16
US9737540B2 (en) 2017-08-22
PH12014500943A1 (en) 2014-06-30
KR102035361B1 (ko) 2019-11-08
CN103945849B (zh) 2017-04-26
LT2785349T (lt) 2019-12-10
HRP20191982T1 (hr) 2020-02-07
DK2785349T4 (da) 2023-01-09
PL2785349T3 (pl) 2020-03-31
FI2785349T4 (fi) 2023-02-09
MX367640B (es) 2019-08-29
SI2785349T2 (sl) 2023-01-31
RU2014119713A (ru) 2016-01-27
CA2856646C (en) 2020-01-14
ES2762250T5 (es) 2023-01-05
JP2015500225A (ja) 2015-01-05
NZ625611A (en) 2016-10-28
AU2012321110A1 (en) 2013-06-20
PT2785349T (pt) 2019-12-11
US20160151373A1 (en) 2016-06-02
CA2856646A1 (en) 2013-06-06
HRP20191982T4 (hr) 2023-01-06
JP6309454B2 (ja) 2018-04-11

Similar Documents

Publication Publication Date Title
AU2012321110B2 (en) Combination treatment
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP2012515184A (ja) 大腸がんの治療方法
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
JP2025509278A (ja) 小細胞肺癌を治療する方法
WO2022218956A1 (en) Combination comprising ribociclib and amcenestrant
CN115038447A (zh) 用于治疗癌症的组合疗法
EP2694056B1 (en) Therapeutic treatment
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
JP6708634B2 (ja) 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ
NZ625611B2 (en) Combination treatment of cancer
HK1202253B (en) Combination treatment of cancer
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
BR112014012261B1 (pt) Combinação e uso de (s)-4-amino-n-(1-(4-clorofenil)-3- hidroxipropil)-1-(7h-pirrolo [2,3-d] pirimidin-4-il)piperidina-4- carboxamida com um modulador da sinalização do receptor de androgênio
HK1193771B (en) Therapeutic treatment
TW201601726A (zh) 骨髓化生不良症候群之治療

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)